Wound Healing Activity of Calotropis Procera Root Bark on Diabetic Rats

Herbal therapy and herbal medicine in traditional medicine as well as in alternative medicine practiced in the developed world. There is recent most of the harbal formulation are used to cure & improve the humal life. The present study Wound healing activity of Calotropis procera root bark on diabetic rats in that root bark is extracted from ethanolic extract using soxhlet method. The pharmacognostic study was done after that phytochemical characters should be studied. The root bark has alkaloids, Flavonoids, steroids and tannins active constituents.  Acute toxicity study carried out with three pharmacological models Incision model, Excision model, and Dead space model. All the extract show predominant activity against selected species. Extract shows beneficial effect on diabetic wound it heals in time with standard component. Overall results of this study reveals that this is an effective extract on diabetic wound. Keywords: Traditional medicine, Calotropis procera, Wound Healing Activit

A Review on Pharmacological Activities of Calotropis Procera

The plant Calotropis procera  (Aiton) Dryand belong to the Apocynaceae family it is popularly known as “Rui” in Marathi, “ Mudar” in hindi other common name include Rubber Bush, Apple of sodom. (India & Pakistan). The bark and leaves are known to show wound healing, shows anti-Hyperglycemic effect, Analgesic, Anti pyretic, neuromuscular blocking activity, Purgative, anti-cancer activities. The phytochemistry of plant reveals presence of triterpenoids, flavonoids, cardiac glycosides, cardenolides, anthocyanins, α-amyrin, β-amyrin, lupeol, β-sitosterol, flavanols, mudarine, resins, a powerful bacteriolytic enzyme calactin, a nontoxic proteolytic enzyme calotropin, and a wax was isolated from the heartwood of Calotropis procera. The present review focuses on pharmacological activities of Calotropis procera. Keywords:  Calotropis procera, anti- Hyperglycemic effect, wound healing, pharmacological activities

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Protocadherin-1 is essential for cell entry by New World hantaviruses

International audienceThe zoonotic transmission of hantaviruses from their rodent hosts to humans in North and South America is associated with a severe and frequently fatal respiratory disease, hantavirus pulmonary syndrome (HPS)1,2. No specific antiviral treatments for HPS are available, and no molecular determinants of in vivo susceptibility to hantavirus infection and HPS are known. Here we identify the human asthma-associated gene protocadherin-1 (PCDH1)3-6 as an essential determinant of entry and infection in pulmonary endothelial cells by two hantaviruses that cause HPS, Andes virus (ANDV) and Sin Nombre virus (SNV). In vitro, we show that the surface glycoproteins of ANDV and SNV directly recognize the outermost extracellular repeat domain of PCDH1-a member of the cadherin superfamily7,8-to exploit PCDH1 for entry. In vivo, genetic ablation of PCDH1 renders Syrian golden hamsters highly resistant to a usually lethal ANDV challenge. Targeting PCDH1 could provide strategies to reduce infection and disease caused by New World hantaviruses